Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Psoriasis
Interventions
DRUG

Certolizumab Pegol (Cimzia®)

"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use~* Dose and Administration details :~ 2 x 1 mL Certolizumab Pegol at Week 0, followed by~* 1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10~* 2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10"

Trial Locations (14)

Unknown

Besançon

Créteil

Nice

Paris

Pierre-Bénite

Berlin

Bonn

Essen

Frankfurt

Hamburg

Kiel

Mahlow

Mainz

Münster

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY